These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 28462446)

  • 21. Assessment of tumor response to neoadjuvant chemotherapy in patients with breast cancer using MRI and FDG-PET/CT-RECIST 1.1 vs. PERCIST 1.0.
    Kitajima K; Miyoshi Y; Yamano T; Odawara S; Higuchi T; Yamakado K
    Nagoya J Med Sci; 2018 May; 80(2):183-197. PubMed ID: 29915436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of response to stereotactic body radiation therapy for nonsmall cell lung cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Han J; Song Q; Guo F; Du R; Fang H; Kang J; Lu Z
    Nucl Med Commun; 2022 Jun; 43(6):717-724. PubMed ID: 35354781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline and early
    Lasnon C; Morel A; Aide N; Silva AD; Emile G
    Cancer Imaging; 2024 Jul; 24(1):90. PubMed ID: 38982546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.
    Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR
    Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Value of
    Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early
    Skougaard K; Nielsen D; Jensen BV; Pfeiffer P; Hendel HW
    Acta Oncol; 2016; 55(9-10):1175-1182. PubMed ID: 27548393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of
    Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y
    Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A role of FDG-PET/CT for response evaluation in metastatic breast cancer?
    Hildebrandt MG; Naghavi-Behzad M; Vogsen M
    Semin Nucl Med; 2022 Sep; 52(5):520-530. PubMed ID: 35525631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L; Cervino AR; Michieletto S; Saibene T; Orvieto E; Bozza F; Ghiotto C
    Q J Nucl Med Mol Imaging; 2017 Jun; 61(2):205-215. PubMed ID: 25501326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An evaluation of the response to neoadjuvant chemotherapy for osteosarcoma of extremities: PERCIST versus RECIST 1.1 criteria after long-term follow-up.
    Xu J; Li Y; Xie L; Sun X; Cai Z; Wang S; Wang Q; Sun K; Guo W
    Ann Nucl Med; 2022 Jun; 36(6):553-561. PubMed ID: 35380350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison Between
    Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
    J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.
    Pinker K; Riedl C; Weber WA
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):55-66. PubMed ID: 28361188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
    Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
    Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response.
    Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK
    Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [18F]FDG PET/CT-based response assessment of stage IV non-small cell lung cancer treated with paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches.
    de Jong EE; van Elmpt W; Leijenaar RT; Hoekstra OS; Groen HJ; Smit EF; Boellaard R; van der Noort V; Troost EG; Lambin P; Dingemans AC
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):8-16. PubMed ID: 27600280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
    De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
    J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of prognostic value of different metabolic response criteria determined by PET/CT in patients with metastatic breast cancer under CDK 4/6 inhibitor treatment.
    Önner H; Eren OÖ; Körez MK; Yilmaz F; Kara Gedik G
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(5):319-324. PubMed ID: 37030597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the RECIST and PERCIST criteria in solid tumors: a pooled analysis and review.
    Min SJ; Jang HJ; Kim JH
    Oncotarget; 2016 May; 7(19):27848-54. PubMed ID: 27036043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors.
    Yanagawa M; Tatsumi M; Miyata H; Morii E; Tomiyama N; Watabe T; Isohashi K; Kato H; Shimosegawa E; Yamasaki M; Mori M; Doki Y; Hatazawa J
    J Nucl Med; 2012 Jun; 53(6):872-80. PubMed ID: 22582049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST).
    Ding Q; Cheng X; Yang L; Zhang Q; Chen J; Li T; Shi H
    J Thorac Dis; 2014 Jun; 6(6):677-83. PubMed ID: 24976990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.